Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022

Latest Articles

  • You have access
    Gastrointestinal safety and tolerability of non-selective non-steroidal anti-inflammatory agents and cyclooxygenase-2–selective inhibitors
    David A. Peura, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 1) SI-31-SI-39;
  • You have access
    Pathogenic mechanisms in giant cell arteritis
    Cornelia M. Weyand, MD and Jörg J. Goronzy, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-28-SII-32;
  • You have access
    Epidemiology of Wegener’s granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome
    Richard A. Watts, DM, FRCP, David G.I. Scott, MD, FRCP and Suzanne E. Lane, MB, MRCP
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-84;
  • You have access
    Understanding the pathogenesis of ANCA: Where are we today?
    Gloria A. Preston, PhD, Jia Jin Yang, MD, Hong Xiao, MD and Ronald J. Falk, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-51-SII-54;
  • You have access
    Contribution of Activated Neutrophils and Mpo-Anca to the Development of Crescentic Glomeru-Lonephritis in Scg/Kj Mice
    A Ishida-Okawara, T Ito-Ihara, T Ono, E Muso, K Saiga, K Nemoto and K Suzuki
    Cleveland Clinic Journal of Medicine April 2002, 69 (4 suppl 2) SII-13-SII-14;
  • You have access
    Improving the care of patients dying of heart failure
    Nancy M. Albert, MSN, RN, Mellar Davis, MD and James Young, MD
    Cleveland Clinic Journal of Medicine April 2002, 69 (4) 321-328;

    Too many heart failure patients die in pain, short of breath, and with too much left unsaid. We can do better for them.

  • You have access
    How to use nesiritide in treating decompensated heart failure
    Roger M. Mills, MD and Robert E. Hobbs, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 252-256;

    Nesiritide, a recombinant formulation of BNP, is the first new parenteral drug in more than a decade to be approved for treating heart failure.

  • You have access
    How to assess and counsel the older driver
    Barbara J. Messinger-Rapport, MD, PhD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 184-192;

    Suggesting that a patient stop driving is never easy, yet taking no action may have deadly consequences.

  • You have access
    The B-type natriuretic peptide assay: A rapid test for heart failure
    W. Frank Peacock, MD
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 243-251;

    This 15-minute test is highly sensitive and fairly specific and is useful in evaluating suspected heart failure in outpatients and in emergency care.

  • What is hemochromatosis?
    You have access
    What is hemochromatosis?
    Cleveland Clinic Journal of Medicine March 2002, 69 (3) 238;

Pages

  • Previous
  • Next
  • 1
  • …
  • 391
  • 392
  • 393
  • 394
  • 395
  • 396
  • 397
  • 398
  • 399
  • …
  • 799

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire